Skip to content
AASLD Family of Websites: Liver Fellow Network
AASLD.org AASLD Foundation LiverLearning Career Center Journals The Liver Meeting HCV Guidelines
AASLD Logo
AASLD Logo

LFN Main Navigation

  • Topics
    Acute Liver Failure Alcohol-Associated Liver Disease Autoimmune Hepatitis Career Development and Mentorship Cholestatic Liver Disease Complications of Liver Disease and Portal Hypertension Drug-Induced Liver Disease HepMadness Inherited Disorders Liver Anatomy, Development, and Physiology Liver Infections Liver Physiology Liver Related Infections MASLD/MASH Neoplasms of the Liver Pathology Pediatrics Pregnancy-Related Liver Disease Symptoms and Clinical Presentation of Liver Disease and Portal HTN Systemic Conditions with Hepatic Manifestations Transplantation and Surgery Vascular Viral Hepatitis
  • Core Series
    Back to Basics Clinical Pearls Webinars Evidence Corner Pathology Pearls Podcast The Why? Series Tools of the Trade View All Core Series Practice Questions
  • Tweetorials
  • About
  • Core Series
  • Evidence Corner
  • Phase 3 Trial Of Resmetirom In MASH With Liver Fibrosis

Phase 3 Trial of Resmetirom in MASH with Liver Fibrosis

July 3, 2024

Richie Manikat

Share

Copy Link Twitter Facebook

https://pubmed.ncbi.nlm.nih.gov/38324483/

Share

Copy Link Twitter Facebook

Written By:

Richie Manikat

Gastroenterology Fellow, Stanford

Related Content

Does secondary prophylaxis for SBP reduce recurrence?

March 3, 2025

Is a transplant benefit-based allocation for deceased donor livers feasible ?

March 3, 2025

A new second-line therapy for Primary Biliary Cholangitis: Elafibranor

December 13, 2024

AASLD LFN Logo

Follow Us

Disclaimer & Privacy Policy

© 2025 American Association for the Study of Liver Diseases